Article Text

Download PDFPDF
178 Long-term efficacy of ocrelizumab in relapsing multiple sclerosis
  1. Gavin Giovannoni1,
  2. Stephen L Hauser2,
  3. Bruno Brochet3,
  4. Xavier Montalban4,
  5. Robert T Naismith5,
  6. Jerry S Wolinsky6,
  7. Stanislas Hubeaux7,
  8. Lahar Mehta8,
  9. Fabian Model7,
  10. Ludwig Kappos9
  1. 1Barts and London School of Medicine/Dentistry, London
  2. 2University of California, San Francisco, USA
  3. 3University of Bordeaux, France
  4. 4Division of Neurology, University of Toronto, Canada
  5. 5Washington University School of Medicine, USA
  6. 6McGovern Medical School, The University of Texas Health Science Center at Houston, USA
  7. 7F. Hoffmann-La Roche Ltd, Basel, Switzerland
  8. 8Genentech, Inc., South San Francisco, USA
  9. 9University Hospital Basel, Switzerland


Background The efficacy and safety of ocrelizumab in relapsing multiple sclerosis were demonstrated in the double-blind control period of the Phase III OPERA I/II trials (NCT01247324/NCT01412333). Here we assessed the efficacy of switching to or maintaining ocrelizumab therapy after 3 years’ follow-up in the open-label extensions (OLEs) of these studies.

Methods At OLE commencement, patients continued ocrelizumab (OCR-OCR) or switched from interferon-β-1a (IFN) to ocrelizumab (IFN-OCR). Adjusted annualised relapse rate (ARR) and time-to-onset of 24-week confirmed disability progression (CDP24) were analysed.

Results Among IFN-OCR patients, ARR decreased from 0.20 in the year pre-switch to 0.10, 0.08 and 0.07 at Years 1, 2 and 3 post-switch. OCR-OCR continuers maintained low ARRs through the year pre-OLE and the 3 years of OLE (0.13, 0.11, 0.08, 0.07). CDP24 was less frequent in OCR-OCR continuers versus IFN-OCR switchers in the year pre-switch and Years 1, 2 and 3 of OLE (7.7%/12.0%, 10.1%/15.6%, 13.9%/18.1% and 16.1%/21.3%; p<0.05, all comparisons).

Conclusions Switching from IFN to ocrelizumab at the start of the OLE provided rapid reductions in ARR, maintained throughout the 3-year follow-up. After 5 years’ follow-up, patients who initiated ocrelizumab 2 years earlier accrued significant, sustained reductions in disability progression compared with patients switching from IFN.

Disclosures Sponsored by F. Hoffmann-La Roche Ltd; writing and editorial assistance was provided by Articulate Science, UK, and funded by F. Hoffmann-La Roche Ltd.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.